Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas

Alexander Fort, Nicholas Fort, Camillo Ricordi, Cherie Stabler

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


The use of cell-based treatments in the field of metabolic organs, particularly the pancreas, has seen tremendous growth in recent years. The transplantation of islet of Langerhans cells for the treatment of type 1 diabetes mellitus (TIDM) has allowed for natural glycemic control for patients plagued with hypoglycemia unawareness. The transplantation of islet cells into the portal vein of the liver, however, has presented challenges to the survival of the cells due to inflammation, vascularization, the need for systemic immunosuppression, and physical stress on the graft. New advances in the engineering of appropriate biohybrid devices and encapsulation technologies have led to promising alternatives to traditional methods.

Original languageEnglish (US)
Pages (from-to)997-1003
Number of pages7
JournalCell Transplantation
Issue number9
StatePublished - Dec 1 2008


  • Bioartificial pancreas
  • Biohybrid device
  • Diabetes
  • Encapsulation

ASJC Scopus subject areas

  • Cell Biology
  • Transplantation
  • Biomedical Engineering


Dive into the research topics of 'Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas'. Together they form a unique fingerprint.

Cite this